ArticlePloS one2026
UBE2S emerges as a key driver in an NK cell-based prognostic model for clear cell renal cell carcinoma.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClear cell renal cell carcinoma (ccRCC) is highly heterogeneous, and robust biomarkers for risk stratification and therapeutic guidance remain limited.
methodsWe integrated single-cell RNA sequencing (scRNA-seq) of tumor and adjacent tissues with multi-cohort transcriptomic validation. High-dimensional weighted gene co-expression network analysis (hdWGCNA) was applied to identify pathogenic immune subsets and candidate genes. Prognostic modeling was performed using CoxBoost, and UBE2S function was validated by in vitro knockdown assays.
resultsscRNA-seq revealed extensive remodeling of the tumor microenvironment, highlighting NK cell subpopulations with strong intercellular signaling. hdWGCNA identified 12 core genes enriched in protein processing and MAPK pathways, with UBE2S emerging as the top driver. A CoxBoost-based 12-gene signature demonstrated robust predictive accuracy across independent datasets. Functionally, UBE2S knockdown suppressed ccRCC cell proliferation and migration, while immune correlation analyses linked UBE2S to altered tumor immunogenicity and genomic stability.
conclusionsOur study identifies NK cell subsets and UBE2S as key contributors to ccRCC progression and establishes a clinically relevant 12-gene prognostic model, offering potential targets for precision therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.